ERCC1和TS对奥沙利铂和5-Fu联合化疗的胃癌患者化疗疗效的Meta分析  

Meta Analysis of ERCC1 and TS in Gastric Cancer Patients treated with Chemotherapy of 5-Fu and Oxaliplatin

作　　者：赵国华[1] 吴杰[1] 范中宝[1] 刘信[2] 张睿[2] 许国岩 

机构地区：[1]辽宁省人民医院普外一科,110016 [2]辽宁省肿瘤医院大肠外科,110042 [3]辽宁陆军预备役高炮一师三团卫生队,110001

出　　处：《实用癌症杂志》2014年第6期657-659,665,共4页The Practical Journal of Cancer

基　　金：辽宁省人社厅百千万人才工程基金资助项目(2011921027);辽宁省科技厅博士启动基金资助项目(20081032)

摘　　要：目的分析ERCC1和TS对预测采用奥沙利铂和5-Fu联合化疗胃癌患者化疗疗效的作用。方法检索纳入5篇(从2008年到2013年)国际和国内有关ERCC1和TS关于预测5-Fu和奥沙利铂对于胃癌化疗疗效的文献,应用随机效应模型和固定效应模型进行综合的定量分析,软件为RevMan5.0。结果 ERCC1对采用5-Fu和奥沙利铂联合化疗的胃癌患者化疗疗效的RR值为0.74,95%CI为0.58-0.95。TS对采用5-Fu和奥沙利铂联合化疗的胃癌患者化疗疗效的RR值为7.55,95%CI为4.47-12.76。结论 ERCC1阴性的胃癌患者,采用5-Fu和奥沙利铂化疗的疗效更好。TS阳性的胃癌患者,采用5-Fu和奥沙利铂化疗的疗效更好。Objective To study the efficacy of ERCC1 and TS in gastric cancer patients who received chemotherapy of5-Fu and oxaliplatin. Methods 5 papers( from 2008 to 2013) of international and domestic study about ERCC1 and TS on the prediction of 5-Fu and oxaliplatin for gastric cancer were collected and analyzed with RevMan5. 0. Random effect model and fixed effect model were applied for data processing. Results The RR value of ERCC1 in gastric cancer patients who received 5-Fu and oxaliplatin was 0. 74,95% of CI was 0. 58-0. 95. The RR value of TS in gastric cancer patients who received 5-Fu and oxaliplatin was 7. 55,95% of CI was 4. 47-12. 76. Conclusion 5-Fu and oxaliplatin for ERCC1 negative gastric cancer patients has good curative effects. 5-Fu and oxaliplatin for TS positive gastric cancer patients has better curative effects.

关 键 词：ERCC1 5-FU 胃癌 META分析 

分 类 号：R735.2[医药卫生—肿瘤]